Rimegepant
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Rimegepant. The dose is 75mg orally disintegrating table. Fully referenced neurology checklist.
Dose
- The dose is 75mg orally disintegrating table
- It is placed on or under the tongue and swallowed without liquid
- The maximum dose is 75mg in 24 hours
Indication
Locked: subscribe to see this section.
Contraindications
Locked: subscribe to see this section.
Side effects
Locked: subscribe to see this section.
References
- Scott LJ. Rimegepant: first approval. Drugs 2020; 80:741-746.
- Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet 2019; 394:737-745.
- Lipton RB, Croop R, Stock EG, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med 2019; 381:142-149.
- Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet 2021; 397:51-60.
- Gago-Veiga AB, Lopez-Rodriguez AB, Sanchez Jimenez M, et al. Rimegepant for migraine prevention in clinical practice: A multicenter study including patients with prior anti-CGRP monoclonal antibody failure (GEMA project). Cephalalgia 2026; 46:3331024261462836.
- And 1 more. Subscribe to see the full list
